{"nctId":"NCT01028391","briefTitle":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","startDateStruct":{"date":"2007-09-01","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":317,"armGroups":[{"label":"Sitagliptin + Pioglitazone","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.","Drug: Metformin"]},{"label":"Pioglitazone + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.","Drug: Metformin"]}],"interventions":[{"name":"Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.","otherNames":[]},{"name":"Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.","otherNames":[]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must complete the double-blind base study (MK-0431-064-00)(NCT00397631) and have at least 75% compliance with study medication during the base study treatment period.\n* Women of childbearing potential must continue to comply with the protocol-specified contraceptive methods","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54","description":"HbA1c is measured as percent. Thus this change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.37","spread":null},{"groupId":"OG001","value":"-1.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54","description":"Change from baseline at Week 54 is defined as Week 54 minus Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.3","spread":null},{"groupId":"OG001","value":"-52.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":164},"commonTop":["All Infections and Infestations","Nasopharyngitis"]}}}